NCT00364143View on ClinicalTrials.gov

Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

June 30, 2011

Conditions
Cancer
Interventions
DRUG

IHL-305 (irinotecan liposome injection)

Trial Locations (2)

37203

Sarah Cannon Cancer Center, Nashville

37232-6307

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
lead

Yakult Honsha Co., LTD

INDUSTRY

NCT00364143 - Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors | Biotech Hunter | Biotech Hunter